Global AI Drug Discovery Research Center and Amgen Korea Sign MOU for AI-Based Drug Discovery Collaboration N
- Date2025.11.18
- 288
AI-Powered Drug Development, Technology Exchange, and Talent Training
The Global AI Drug Discovery Research Center at Ewha Womans University (Director: Choi Seon) signed a memorandum of understanding (MOU) with Amgen Korea, a global biotechnology company led by CEO Shin SuHee, on November 10 (Mon) at Amgen Korea’s Seoul Jung-gu office to collaborate on artificial intelligence (AI)-based drug discovery.
(From left) Director Choi Seon and CEO Shin SuHee.
The agreement aims to enhance the feasibility and industrial applicability of AI-driven drug discovery by promoting practical cooperation between the two institutions in talent cultivation, technological exchange, and research related to AI-based drug development.
Under the MOU, the two organizations plan to pursue:
▲ mutual cooperation in AI-based drug discovery and related research
▲ academic exchange through seminars, research presentations, and invited lectures
▲ joint education and internship programs for the training of specialists
▲ and other collaborative initiatives mutually recognized as necessary.
Choi Seon, director of the Global AI Drug Discovery Research Center, stated, “Through this agreement, we expect to build an industry–academia collaboration model that generates concrete outcomes by expanding mutual cooperation and academic exchange with Amgen Korea in AI-based research. The Ewha Womans University Global AI Drug Discovery Center will continue to contribute to strengthening the national pharmaceutical industry’s competitiveness by advancing industrial development and training specialized talent based on AI technologies.”
Shin SuHee, CEO of Amgen Korea, remarked, “This agreement marks an opportunity to create synergy by combining Amgen’s experience with AI technologies and Ewha Womans University’s strong research capabilities. As AI-based drug discovery can present a new paradigm for treating patients suffering from severe diseases, we will continue to collaborate with domestic research institutes, healthcare professionals, and biotech ventures.”
(From left) Cha SeonSin, professor of Chemistry and Nano Science; Lee JeongYeon, professor of Pharmacy; Lee HwaJeong, dean of the College of Pharmacy; Choi Seon, director of the Global AI Drug Discovery Research Center; Shin SuHee, CEO of Amgen Korea; Kim KyunJi, executive director of Medical Affairs; Kim SeoHyun, senior director of Corporate Affairs; Park HyeRin, director of Medical Affairs; Lee SeungJae, director; and Hwang SeonJin, senior director of Clinical Development.
Amgen, a global pharmaceutical company, has been a leader in integrating advanced technologies—including AI—across all stages of drug development, strengthening its leadership in healthcare-related AI. Through its subsidiary deCode genetics, the company analyzes extensive genomic data to deepen understanding of diseases and identify new therapeutic candidates. Amgen has also developed AI and machine learning (ML) tools such as ATOMIC for clinical trial optimization and AMPLIFY for protein structure generation, accelerating innovation by enhancing efficiency and speed in the drug development process.
Amgen Korea continues to extend this global innovation into the domestic landscape. Its efforts to expand access to medicines for patients with severe diseases and to foster the biotechnology ecosystem were recognized by the Ministry of Health and Welfare, which certified the company as an Innovative Pharmaceutical Company in 2024.
Meanwhile, the Global AI Drug Discovery Research Center at Ewha Womans University was established in 2020 to reduce the substantial time and cost associated with research and development (R&D) and to maximize efficiency and success rates in drug discovery using the latest AI technologies. The center continues to produce world-class research outcomes through active multidisciplinary convergence research and is building an innovative research ecosystem through global collaboration and partnerships across industry, academia, research institutes, and medical institutions.